

Applicants: Short et al.
Application No: 10/599,943
Amendment After Final Rejection
Docket No.: P-7735 (102-682 PCT/US)
Page 2

AMENDMENTS TO THE CLAIMS:

The following list of claims will replace all prior versions, and listings, of claims. Please amend the claims as follows:

1. (Currently Amended) A method for the selective disassociation of at least one biological entity from a plasma polymerized surface of an organic monomer including an allylamine, said method comprising:
contacting said surface with at least one agent having a salt concentration of about 400 500 mM NaCl to about 2 M NaCl, wherein said agent provides for selective disassociation of said entity from said plasma polymerized surface.
2. (Original) A method according to Claim 1 wherein said biological entity is a carbohydrate.
3. (Original) A method according to Claim 2 wherein said carbohydrate is a homopolysaccharide.
4. (Original) A method according to Claim 2 wherein said carbohydrate is a heteropolysaccharide.
5. (Original) A method according to Claim 4 wherein said heteropolysaccharide is a glycosaminoglycan.
6. (Currently amended) A method according to Claim 2 any-of Claims 2-5 wherein said carbohydrate is a sulphated biomolecule.
7. (Previously presented) A method according to Claim 5 wherein said glycosaminoglycan is selected from the group consisting of: hyaluronan; dermatan sulfate; chondroitin sulphate; heparin; heparan sulphate; and keratan sulphate.

Applicants: Short et al.
Application No: 10/599,943
Amendment After Final Rejection
Docket No.: P-7735 (102-682 PCT/US)
Page 3

8. (Original) A method according to Claim 1 wherein said biological entity is a polypeptide.
9. (Original) A method according to Claim 1 wherein said biological entity is a nucleic acid molecule.
10. (Previously presented) A method according to claim 9 wherein said nucleic acid molecule is selected from the group consisting of deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and peptide oligonucleotides (PNAs).
11. (Original) A method according to Claim 1 wherein said biological entity is a cell or viral particle.
12. (Previously presented) A method according to Claim 1 wherein said surface comprises a plasma polymer of a volatile acid.
13. (Previously presented) A method according to Claim 12 wherein said surface comprises at least 5% of said volatile acid.
14. (Previously presented) A method according to Claim 1 wherein said surface comprises a plasma polymer of a volatile alcohol.
15. (Previously presented) A method according to Claim 1 wherein said surface comprises a plasma polymer of a volatile amine.
16. (Previously presented) A method according to Claim 1 wherein said surface comprises a mixture of volatile acid and volatile hydrocarbon.
- 17-25. (Cancelled).

Applicants: Short et al.
Application No: 10/599,943
Amendment After Final Rejection
Docket No.: P-7735 (102-682 PCT/US)
Page 4

26. (Currently amended) A method according to Claim 6 wherein said sulphated biomolecule glycosaminoglycan is selected from the group consisting of: ~~hyaluronan~~; dermatan sulfate; chondroitin sulphate; heparin; heparan sulphate; and/or keratan sulphate.

27. (Previously presented) A method according to claim 10 wherein said DNA is selected from cDNA, genomic DNA, single stranded DNA and oligonucleotides.

28. (Currently amended) A method according to claim 1, wherein said agent has a salt concentration of about 500 400 mM NaCl to about 1 M NaCl.

29. (Currently amended) A method according to claim 1, wherein said agent has a salt concentration of about 300 750 mM NaCl to about 1 M NaCl.

30. (Cancelled).

31. (Previously presented) A method according to claim 1, wherein said agent has a salt concentration of about 500 mM NaCl to about 750 mM NaCl.